Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing IVF/ICSI
References
Additional references
Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor‐blind controlled trial. Human Reproduction 2006;21(12):3217‐27.
Antoniou M, Jorgensen AL, Kolamunnage‐Dona R. Biomarker‐guided adaptive trial designs in phase II and phase III: a methodological review. PLoS ONE 2016;11(2):1‐30.
Arce JC, Andersen AN, Fernandez‐Sanchez M, Visnova H, Bosch E, Garcia‐Velasco JA, et al. Ovarian response to recombinant human follicle‐stimulating hormone: a randomized, antimullerian hormone‐stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility 2014;102(6):1633‐U456.
Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility 2016;106:1634‐47.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproduction Update 2006;12:685‐718.
Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertility and Sterility 2010;94(3):1044‐51.
Broer SL, Dólleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta‐analysis. Fertility and Sterility 2013;100(2):420‐9.
Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. on behalf of the IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update 2013;19(1):26‐36.
Calhaz‐Jorge C, De Geyter C, Kupka MS, de Mouzon, Erb K, Mocanu E, et al. Assisted reproductive technology in Europe, 2012: results generated from European registers: results generated from European registers by ESHRE. Human Reproduction 2016;31(8):1638‐52.
Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D’Hooghe T, Castilla JA, et al. European IVF‐Monitoring Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Human Reproduction 2014;29:2099‐113.
Ferraretti A, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction April 2011;26(7):1616‐24.
GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 01/06/2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Gunby J, Bissonnette F, Librach C, Cowan L. Assisted reproductive technologies (ART) in Canada: 2006 results from the Canadian ART Register. Fertility and Sterility 2010;93:2189‐201.
The Harbin Consensus Workshop Group. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement. Human Reproduction 2014;29(10):2075‐82.
Harris K, Fitzgerald O, Paul R C, Macaldowie A, Lee E, Chambers GM. Assisted reproductive technology in Australia and New Zealand 2014. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales2016.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Human Reproduction 2016;31(9):1997‐2004.
Kawwass JF, Kissin DM, Kulkarni AD, Creanga AA, Session DR, Callaghan WM, et al. Safety of assisted reproductive technology in the United States, 2000‐2011. JAMA 2015;313(1):88.
Klinkert ER, Broekmans FJM, Looman CWN, Habbema JDF, te Verde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction 2005;20(3):611‐5.
Lekamge DN, Lane M, Gilchrist RB, Tremellen KP. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. Journal of Assisted Reproduction and Genetics 2008;25(11‐12):515‐21.
Macaldowie A, Wang Y, Chambers G, Sullivan E. Assisted reproductive technology in Australia and New Zealand. Assisted Reproductive Technology in Australia and New Zealand 2011. Sydney: National Perinatal Epidemiology and Statistics Unit, University of New South Wales, 2013.
Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012103.pub2]
Popovic‐Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction 2003;18(11):2275‐82.
Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertility and Sterility 2014;101(4):967‐73.
Sunkara SK, Rittenberg V, Raine‐Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Human Reproduction May 2011;26(7):1768‐74.
Tajik P, Zwinderman AH, Mol BW, Bossuyt PM. Trial designs for personalizing cancer care: a systematic review and classification. Clinical Cancer Research 2013;19(17):4578‐88.
Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R. Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertility and Sterility 2013;99(5):1324‐31.
Vail A, Gardener E. Common statistical errors in the design and analysis of subfertility trials. Human Reproduction 2003;18:1000‐4.
van Tilborg TC, Eijkemans MJ, Laven JS, Koks CA, de Bruin JP, Scheffer GJ, et al. The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. BMC Womens Health 2012;12:1‐7.
Visser JA, de Jong FH, Laven JS, Themmen AP. Anti‐Müllerian hormone: a new marker for ovarian function. Reproduction 2006;131(1):1‐9.
Youssef M, Mourad S. Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD001302]
